Tokunaga Masatoshi, Masuda Aiichiro, Mukai Masaya, Nakamura Hideyuki, Iwaki Koji, Terachi Toshiro
Department of Urology, Tokai University Oiso Hospital, Kanagawa, Japan.
Tokai J Exp Clin Med. 2005 Jul;30(2):111-5.
A 57-year-old woman presented to our hospital with macrohematuria. Renal cell carcinoma (RCC) of the left kidney with bilateral pulmonary and mediastinal lymph node metastases was diagnosed. Radical nephrectomy was performed. Pathological examination confirmed the diagnosis of RCC (pT2pN0M1), so immunotherapy was performed using interleukin-2 (IL-2). The mediastinal lymph node metastases disappeared completely after 5 months of immunotherapy. Investigation of immunological parameters showed an increase of CD8-positive T cells (CD8) and a decrease of CD14-positive cells (CD14), leading to a marked increase of the CD8/CD14 ratio. Although her pulmonary metastases are unchanged, the mediastinal metastases still show complete remission at 14 months postoperatively. The CD8/CD14 ratio may have potential as a new marker for monitoring the response of RCC to immunotherapy and selecting suitable patients for such therapy.
一名57岁女性因肉眼血尿前来我院就诊。诊断为左肾肾细胞癌（RCC）伴双侧肺及纵隔淋巴结转移。行根治性肾切除术。病理检查确诊为RCC（pT2pN0M1），因此使用白细胞介素-2（IL-2）进行免疫治疗。免疫治疗5个月后，纵隔淋巴结转移完全消失。免疫参数调查显示CD8阳性T细胞（CD8）增加，CD14阳性细胞（CD14）减少，导致CD8/CD14比值显著升高。虽然她的肺转移灶未变，但术后14个月纵隔转移仍显示完全缓解。CD8/CD14比值可能有潜力作为监测RCC对免疫治疗反应及选择合适患者进行此类治疗的新标志物。
